Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
复制标题
DOI：
10.1210/jc.2019-00221
复制
发表时间：
2019-05-01
影响因子：
5.8
通讯作者：
Shoback, Dolores
中科院分区：
文献类型：
--
作者：
Eastell, Richard;Rosen, Clifford J.;Shoback, Dolores
目的：我们的目的是制定临床实践指南的药理学管理的骨质疏松症在绝经后women.Conclusions：从临床试验的证据和见解的临床经验与骨质疏松症的药理学治疗进行了严格的评估，制定这一指南的管理绝经后骨质疏松症。在撰写委员会的审议意见时，还考虑了患者的偏好、依从性和持久性数据以及患者和提供者角度的风险和益处。编写委员会成员就四项管理原则达成共识：（i）应使用国家特定的评估工具来确定绝经后妇女未来骨折的风险，以指导决策。(ii)患者的偏好应纳入治疗计划。(iii)营养和生活方式的干预和跌倒预防应伴随所有的药物治疗方案，以减少骨折的风险。(iv)多种药物治疗能够降低绝经后高危女性的骨折发生率，风险-获益和安全性特征可接受。
Objective: The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women.Conclusions: Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles.